Menu

PROGRAM

Saturday, March 25, 2023
(Program subject to change)

7:00-7:45am

Registration/Coffee

7:45-8:45

Product Theatre Breakfast - (Non-CME)
Addressing Risk of HF Rehospitalization With an Additional Guideline-Recommended Medication

Payal Kohli, MD
Learning Objectives:
- Discuss the increased risk of rehospitalization for HF with additional HFH
- Review an outcome study in high-risk patients with HFrEF
Supported by: Merck

8:45-9:00

Introductions, Welcome and Program Overview
Drs. Lori Daniels and Alan Maisel

Session I: Acute Coronary Syndrome and Troponin
Allan Jaffe, MD (Moderator)

9:00-9:15

hsTroponin in the Emergency Department: 0/1h Strategy
Frank Peacock, MD

9:15-9:35

STATE OF THE ART TALK
How Low Can You Go? The Evolution of hsTroponin and Future Applications

Fred Apple, PhD

9:35-9:50

Point of Care hsTroponin for Early Rule-Out of MI: Dawn of a New Age
Pedro Lopez-Ayala, MD, MSc

9:50-10:05

Biomarkers and Type 1 vs Type 2 MI
Yader Sandoval, MD

10:05-10:30

Acute Coronary Syndrome Panel Q&A
Allan Jaffe, MD (Moderator)

10:30-10:50

Coffee Break/Visit Exhibits

Session II: Biomarkers in Heart Failure and CVD Prevention
Alan Maisel, MD (Moderator)

10:50-11:05

Getting to GDMT Targets with STRONG-HF Biomarkers
Gregg Fonarow, MD

11:05-11:20

Cardiologists as Diabeticians: Biomarkers and SGLT2i/GLP1a Treatments
David Berg

11:20-11:35

Uncovering the Real Pandemic – Leveraging Biomarkers to Crack CVD Prevention
Christopher deFilippi, MD

11:35-11:50

Breast Arterial Calcification for Cardiovascular Risk Prediction in Women
Lori Daniels, MD

11:50-12:05pm

Sizing up the Inferior Vena Cava: A Biomarker for all of Heart Failure
Ori Ben-Yehuda, MD

12:05-12:30

Heart Failure Case Q&A Panel
Nick Wettersten, MD (Presenter)


12:30-1:30

Product Theatre Luncheon - (Non-CME)
Is OZEMPIC® Right for Your Patients With Established ASCVD and T2D?

Matthew Budoff, MD
Supported by: Novo Nordisk


Session III: Cardiometabolic Biomarkers and Novel Approaches
Lori Daniels, MD (Moderator)

1:30-1:50

Integrating Biomarkers into Outcomes Trials
Ori Ben-Yehuda, MD

1:50-2:05

Two Heads are Better than One: Joining Biomarkers with CAC for Prediction of ASCVD
Matthew Budoff, MD

2:05-2:20

Practical Application of Biomarkers for Cardiac Rehab and Prevention: Where Biomarkers of Lipids, Glycemia and Inflammation Intersect
Pam Taub, MD

2:20-2:35

Who Invited the Kidney to the Heart Party? Implications of Cardiorenal Biomarkers
Nick Wettersten, MD

2:35-2:50

Biomarkers Come to Hollywood
Alan Wu, PhD

2:50-3:05

Biomarkers in Cardio-Oncology – More than NTpro, Tn and a Buzzword
Anya Narezkina, MD

3:05-3:25

Coffee Break/Visit Exhibits

Session IV: Biomarkers - The Next Generation: EP, Cath Lab and AI
Alan Maisel, MD (Moderator)

3:25-3:40

Next-Generation Machine Learning with 12-lead ECGs to Target and Treat Arrhythmias
David Krummen, MD

3:40-3:55

Biomarkers and Optimizing Therapies for Patients Arrhythmia and Device Patients
Riki Green, MD

3:55-4:10

The Holy Grail: Biomarkers of Vulnerable Plaque
David Erlinge, MD

4:10-4:25

Leveraging Imaging Biomarkers and AI for Radiologic Diagnoses
Albert Hsiao, MD

4:25-4:40

Putting it All Together: Artificial Intelligence in ACS and Heart Failure
Alan Maisel, MD

4:40-4:55

Q&A

4:55-5:00

Concluding Remarks
Drs. Lori Daniels and Alan Maisel

5:00-6:00

Wine and Cheese Reception and Poster Session